Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Status
- WITHDRAWN
- Phase
- PHASE2
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Status
- RECRUITING
- Phase
- PHASE1
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax After TKI to Target Persisting Stem Cells in CML
- Status
- COMPLETED
- Phase
- PHASE2
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1